4.7 Article

Repurposing the oncolytic virus VSV?51M as a COVID-19 vaccine

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Immunology

SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus

Almohanad A. Alkayyal et al.

Summary: Despite recent advances in oncolytic virus research, improving their replication is crucial for enhancing their therapeutic index. This study found that the SARS-CoV-2 spike protein receptor-binding domain (RBD) can enhance viral production and anticancer activity of oncolytic viruses.

FRONTIERS IN IMMUNOLOGY (2023)

Article Medicine, General & Internal

Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants

Ruediger Gross et al.

Summary: According to a study on a cohort of individuals who received heterologous ChAdOx1 nCoV-19 BNT162b2 vaccination, the regimen induced potent humoral and cellular immune responses, with strong neutralization of the most prevalent SARS-CoV-2 variants. The results suggest that this heterologous vaccination regimen is at least as immunogenic and protective as homologous vaccinations and also offers protection against current variants of concern.

EBIOMEDICINE (2022)

Article Multidisciplinary Sciences

A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease

Stephanie L. Foster et al.

Summary: Nipah virus is an emerging highly lethal zoonotic disease that can be transmitted via respiratory droplets. A study has shown that a recombinant vesicular stomatitis virus-based vaccine can rapidly protect monkeys from lethal Nipah virus infection.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

Article Immunology

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Membrane (M) and Spike (S) Proteins Antagonize Host Type I Interferon Response

Qi Zhang et al.

Summary: The study identified that SARS-CoV-2 membrane protein and spike protein antagonize the IFN-I antiviral response through different mechanisms, inhibiting the nuclear translocation of IRF3 and blocking the interaction between STAT1 and JAK1. This research enhances our understanding of SARS-CoV-2 pathogenesis and suggests new therapeutic targets for the treatment of COVID-19.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2021)

Article Polymer Science

Magnetic Field-Assisted Laser Ablation of Titanium Dioxide Nanoparticles in Water for Anti-Bacterial Applications

Hasan H. Bahjat et al.

Summary: Titanium oxide nanoparticles were synthesized by pulsed Nd:YAG laser ablation in water with the assistance of an external magnetic field. Characterization techniques including XRD, FESEM, EDX, TEM, UV-Vis spectroscopy, and Raman spectroscopy were used to investigate the nanoparticles properties. The presence of a magnetic field during synthesis altered the morphology, size, and optical properties of the TiO2 nanoparticles, resulting in enhanced antibacterial effects on S. aureus and E. coli.

JOURNAL OF INORGANIC AND ORGANOMETALLIC POLYMERS AND MATERIALS (2021)

Article Chemistry, Medicinal

Pt(II)-Thiocarbohydrazone Complex as Cytotoxic Agent and Apoptosis Inducer in Caov-3 and HT-29 Cells through the P53 and Caspase-8 Pathways

Abeer A. Ibrahim et al.

Summary: The study showed that the Pt(II)-thiocarbohydrazone complex exhibited significant cytotoxic effects against ovarian and colorectal adenocarcinoma cells, triggering apoptosis through the activation of the p53 and caspase-8 pathways. These findings suggest that the complex could be a promising chemotherapeutic agent for various types of cancer cells.

PHARMACEUTICALS (2021)

Review Immunology

Viral targets for vaccines against COVID-19

Lianpan Dai et al.

Summary: The urgent need for vaccines to control the COVID-19 pandemic has led to the rapid development of multiple vaccine candidates, with some showing positive results in late-stage clinical trials. This article discusses the viral elements used in these candidates, the reasons why they are good targets for the immune system, and their implications for protective immunity. Dai and Gao highlight the importance of selecting the right viral targets in vaccine development to ensure an effective immune response and the overall safety and efficacy of the vaccine.

NATURE REVIEWS IMMUNOLOGY (2021)

Article Medicine, Research & Experimental

Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death

Robert W. Cross et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Review Immunology

The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies

Lea Skak Filtenborg Frederiksen et al.

FRONTIERS IN IMMUNOLOGY (2020)

Article Multidisciplinary Sciences

A single dose of recombinant VSV-G-spike vaccine provides protection against SARS-CoV-2 challenge

Yfat Yahalom-Ronen et al.

NATURE COMMUNICATIONS (2020)

Review Immunology

SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development

Mei-Yue Wang et al.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2020)

Review Medicine, General & Internal

Body Localization of ACE-2: On the Trail of the Keyhole of SARS-CoV-2

Francesca Salamanna et al.

FRONTIERS IN MEDICINE (2020)

Article Nanoscience & Nanotechnology

Dextran-coated superparamagnetic nanoparticles modified with folate for targeted drug delivery of camptothecin

Sharafaldin Al-Musawi et al.

ADVANCES IN NATURAL SCIENCES-NANOSCIENCE AND NANOTECHNOLOGY (2020)

Article Biotechnology & Applied Microbiology

Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens

Anahita Fathi et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)

Review Biotechnology & Applied Microbiology

Oncolytic viruses: a new class of immunotherapy drugs

Howard L. Kaufman et al.

NATURE REVIEWS DRUG DISCOVERY (2015)

Article Biotechnology & Applied Microbiology

rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy

Lan Wu et al.

HUMAN GENE THERAPY (2008)